In this episode, Ara Metjian, MD; Paul Coppo, MD, PhD; and Marshal Mazepa, MD, answer questions from an audience of healthcare professionals on topics related to the management of acquired thrombotic thrombocytopenic purpura (aTTP), including: Rationale of the CAPLAVIE regimen of caplacizumab with corticosteroids and rituximab in aTTP in the acute phaseData for caplacizumab in pediatric patients with aTTPInitiating rituximab after completion of plasma exchangeInternational Society on Thrombosis and Haemostasis guideline recommendations against using aspirinTriggers of aTTP episodes aside from infectionEffect of COVID-19 vaccines and COVID-19 infections on aTTP onset or relapsePresenters:Ara Metjian, MDAssociate ProfessorDivision of HematologyDepartment of MedicineUniversity of Colorado, Anschutz Medical CampusAurora, ColoradoPaul Coppo, MD, PhDProfessor of HematologyHematology Department, AP-HPSorbonne UniversityParis, FranceMarshall Mazepa, MD Assistant Professor of MedicineDivision of Hematology, Oncology, and TransplantationUniversity of MinnesotaMinneapolis, MinnesotaLink to the complete program, including downloadable slidesets, an expert commentary, an on-demand webcast, and healthcare professional resource guide:https://bit.ly/3J1fcad

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related